City

Beijing (1)

Chang chun (1)

Chengdu (1)

Chongqing (1)

Shanghai (1)

Condition

Gastric and Gastroesophageal Junction Adenocarcinoma (2)

Cervical Cancer (1)

Endometrial Cancer (1)

Esophageal Cancer (1)

NSCLC (1)

Solid Tumor (1)

Overall Status

Not yet recruiting (1)

Recruiting (1)

Sign in for free

Phase

phase 1/phase 2 (2)

Sponsor

Laekna Limited (1)

Yonsei University (1)

Collaborator

Intervention

afuresertib (1)

docetaxel (1)

nab paclitaxel (1)

pembrolizumab (keytruda®), trifluridine/tipiracil (lonsurf®) (1)

sintilimab (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (2)

gastric and gastroesophageal junction adenocarcinoma

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Gastric and Gastroesophageal Junction Adenocarcinoma Trial (Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®))

Not yet recruiting

Gastric and Gastroesophageal Junction Adenocarcinoma

Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)

(no location specified)

Aug 17, 2022

Solid Tumor, NSCLC, Cervical Cancer Trial in China (Afuresertib, Nab paclitaxel, Docetaxel)

Recruiting

Solid Tumor
+5 more

Afuresertib
+3 more

Beijing, Beijing, China
+4 more

Jul 15, 2022